Roche bags 'breakthrough' anti-fibrosis drug in $1.4B biotech buyout deal
Roche is snapping up a “breakthrough” anti-fibrotic drug in a $1.4 billion buyout.
The pharma giant announced Friday that it is acquiring Promedior, primarily to get its hands on PRM-151, a recombinant form of human pentraxin-2 (PTX-2) protein that has nailed down mid-stage clinical data on idiopathic pulmonary fibrosis and demonstrating its potential for a range of fibrotic conditions.
The investors will get $390 million in cash with $1 billion of milestones on the table as Roche carries the ball from here.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
